<DOC>
	<DOCNO>NCT00345657</DOCNO>
	<brief_summary>The purpose study investigate benefit combination niacin ER/lovastatin patient receive standard care LDL goal per ATP III guideline .</brief_summary>
	<brief_title>Efficacy Study Extended-Release Niacin/Lovastatin Versus Usual Care</brief_title>
	<detailed_description>Both LDL HDL important contributor pathophysiology atherosclerosis coronary artery disease ( CAD ) ; however , HDL often ignore primary care . The combination niacin extended-release ( ER ) /lovastatin single tablet formulation ( AdvicorÂ® ) may effective therapeutic option simultaneously correct lipoprotein abnormality reduce CAD risk . The purpose study investigate benefit combination niacin ER/lovastatin patient receive standard care LDL goal per ATP III guideline .</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hyperlipidemia , Familial Combined</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Lovastatin</mesh_term>
	<mesh_term>L 647318</mesh_term>
	<mesh_term>Dihydromevinolin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>1 . &gt; 18 year old CAD risk factor CAD 2. standard care Family Medical Care Tulsa 3. LDL goal per ATP III guideline 1. pregnancy/lactating 2. liver disease 3. allergy statin niacin 4. active peptic ulcer disease 5. previous treatment combination therapy dyslipidemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>Hyperlipidemia</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Niacin</keyword>
	<keyword>Hydroxymethylglutaryl-CoA Reductase Inhibitors</keyword>
	<keyword>Combination lipid therapy</keyword>
	<keyword>Lovastatin</keyword>
</DOC>